Aurinia to Provide Update on Lupus Nephritis Trial Results at Select Event on Friday

Ines Martins, PhD avatar

by Ines Martins, PhD |

Share this article:

Share article via email
lupus nephritis study update

Aurinia Pharmaceuticals recently announced that it will host a lupus nephritis (LN) expert breakfast on Friday, Sept. 30, from in New York, to present recently released results from the AURA-LV trial in patients with active LN.

The Phase 2b clinical trial (NCT02141672) is a randomized, controlled double-blind study comparing the efficacy and safety of voclosporin (23.7 mg or 39.5 mg) in achieving remission in patients with active LN. The study enrolled 265 patients at multiple centers across 20 countries, each with an LN diagnosis according to criteria defined by the American College of Rheumatology, and clinical and biopsy features indicative of highly active LN.

The trial compared the efficacy of voclosporin combined with current standard of care mycophenolate mofetil (MMF) against a combination of standard of care with placebo in achieving complete remission. Both groups received low doses of corticosteroids as background therapy.

At the breakfast meeting, which runs from 8:00 to 9:30 a.m. EDT,  the company will review top-line results and announce additional data, including pre-specified analyses, secondary endpoints and additional subset analyses, from the trial.

Also featured will be a discussion — led by nephrologists David R. W. Jayne, MD, director of the Vasculitis and Lupus Clinic at the University of Cambridge, and William Pendergraft III, MD, PhD, an assistant professor of Medicine in the Division of Nephrology & Hypertension at UNC School of Medicine – on the current standard of care of LN and perspectives  for the future of voclosporin.

Voclosporin is an investigational, potentially best-in-class calcineurin inhibitor (CNI), which means it blocks IL-2 expression and T-cell-mediated immune responses. The drug acts as an immunosuppressant with a synergistic and dual mechanism of action, and has the potential to improve near- and long-term outcomes in LN when added to standard of care.

Participation in the breakfast is restricted to investors, sell-side analysts, and business development professionals, and reservations can be made by emailing LifeSci Advisors. Seats at the event are limited.

According to a press release, a live webcast of the event, including slides, will be available on the investors’ section of Aurinia Pharmaceuticals’ website.